ReviewExpert opinion on drug delivery2018
Changing the pill: developments toward the promise of an ultra-long-acting gastroretentive dosage form.
Review in Expert opinion on drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Bacteria-mimetic bioadhesives with multivalent mucoadhesion and drug-compatible delivery.Materials horizons · 2026Article
- An ingestible origami-inspired metamaterial for prolonged oral delivery of therapeutics.Nature communications · 2026Article
- Electroadhesion of polymer networks by polycation interfacial bridging: sticky electrophoresis, ionic complexation, and chain entanglement.bioRxiv : the preprint server for biology · 2026Article
- Optimization and evaluation of gastro-expandable film of Eudragit S100 and ethylcellulose by using the design of experiment.Scientific reports · 2026Article
- Advancements and Challenges in Gastroretentive Drug Delivery Systems: A Comprehensive Review of Research Innovation, Technologies, and Clinical Applications.Recent advances in drug delivery and formulation · 2026Review
- Modular Titratable Polypills for Personalized Medicine and Simplification of Complex Medication Regimens.Advanced healthcare materials · 2023Article
- Development of a Swellable and Floating Gastroretentive Drug Delivery System (Pharmaceutics · 2023Article
- β-Glucan and Fatty Acid Based Mucoadhesive Carrier for Gastrointestinal Tract Specific Local and Sustained Drug Delivery.Biomolecules · 2023Article
- Utilizing 4D Printing to Design Smart Gastroretentive, Esophageal, and Intravesical Drug Delivery Systems.Advanced healthcare materials · 2023Review
- Expandable Drug Delivery Systems Based on Shape Memory Polymers: Impact of Film Coating on Mechanical Properties and Release and Recovery Performance.Pharmaceutics · 2022Article
- The Development of Innovative Dosage Forms of the Fixed-Dose Combination of Active Pharmaceutical Ingredients.Pharmaceutics · 2022Review
- Foundations of gastrointestinal-based drug delivery and future developments.Nature reviews. Gastroenterology & hepatology · 2022Review
- Mucosa-interfacing electronics.Nature reviews. Materials · 2022Review
- Combating iron overload: a case for deferoxamine-based nanochelators.Nanomedicine (London, England) · 2020Article
- A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Untethered shape-changing devices in the gastrointestinal tract.Expert opinion on drug deliveryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe development of oral sustained release dosage forms has been a longstanding goal due to the potential for ease of administration, improved pharmacokinetics, reduced dosing frequency, and improved adherence. The benefits of multiday single-dose drug delivery are evident in the success and patient adoption of injected and implanted dosage forms. However, in the space of oral medications, all current commercially available gastric resident dosage forms, and most in development, are limited to gastric residence of less than 1 day. AREAS COVERED: Reviews of systems to extend gastric residence reveal that 1 day or more residence has been an unmet challenge. New dosage forms are in development that seek to address many of the key physiological and design challenges of long-term gastric retention beyond 24 h and up to a week or longer. The present analysis highlights the design, material considerations and implications of unfolding dosage form systems with ultra-long-term gastric residence. EXPERT OPINION: The development of oral dosage forms providing sustained release of high potency medications over days or weeks could transform care, significantly decrease patient burden in chronic disease management and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.